<DOC>
	<DOCNO>NCT02260076</DOCNO>
	<brief_summary>To assess safety tolerance 5 mL 20 mL PEG 400 multiple rising dos</brief_summary>
	<brief_title>Safety Total Daily Doses Polyethylene Glycol ( PEG ) 400 Administered Orally Healthy Male Human Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject determine result screen Signed write informed consent accordance good clinical practice ( GCP ) local legislation Age ≥ 18 ≤ 55 year Broca ≥ 20 % ≤ + 20 % Any finding medical examination ( include blood pressure , pulse rate electrocardiogram [ ECG ] ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder , include clinical history viral hepatitis , serological evidence active Hepatitis B Hepatitis C infection History orthostatic hypotension , faint spell blackouts Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within one month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within one month prior administration trial Smoker ( &gt; 10 cigarette three cigar three pipes/day ) inability refrain smoke 10 hour morning dose one hour afternoon/evening dose one hour dose Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation within one month prior administration trial Excessive physical activity within five day prior administration trial Any laboratory value outside clinically accept reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>